The abstract is read at the publisher; the summary is JClub's.
ADCE-T02, a tissue factor–targeting ADC with an average drug-to-antibody ratio of 4.5, shows strong preclinical efficacy and is well tolerated in nonhuman primates.
- Why it matters: Tissue factor is overexpressed in multiple cancers, but existing TF-ADCs like tisotumab vedotin cause substantial side effects that limit further development.
- What they did: ADCE-T02 uses Ab-T02 conjugated via a self-immolative linker to exatecan, binds TF with high affinity, triggers internalization and exatecan release, and is tested in diverse xenograft models.
- The result: In vivo, it is highly efficacious across hard-to-treat xenografts and shows favorable pharmacokinetics with no evidence of ocular, skin, lung toxicities, peripheral nerve damage, or bleeding versus tisotumab vedotin in nonhuman primates.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.